What performance-enhancing stimulants mean for economic growth
Could America’s Adderall shortage have harmed its productivity?
Towards the end of last year America began running short of medicines used to treat attention-deficit hyperactivity disorder (adhd), including Adderall (an amphetamine) and Ritalin (a central-nervous-system stimulant). Nine in ten pharmacies reported shortages of the medication, which tens of millions of Americans use to help improve focus and concentration. Around the same time, something intriguing happened: American productivity, a measure of efficiency at work, dropped. In the first quarter of 2023, output per hour fell by 3%.
This article appeared in the Finance & economics section of the print edition under the headline “Buzzkill”
Finance & economics May 27th 2023
- What happens if America defaults on its debt?
- China and Russia compete for Central Asia’s favour
- China’s state capitalists celebrate their soaring shares
- The American credit cycle is at a dangerous point
- What would humans do in a world of super-AI?
- What performance-enhancing stimulants mean for economic growth
More from Finance & economics
Why your portfolio is less diversified than you might think
The most important idea in modern finance has become maddeningly hard to implement
Can Germany’s economy stage an unexpected recovery?
The situation is dire, but there are glimmers of hope
Giorgia Meloni has grand banking ambitions
Will Italy’s nationalist prime minister manage to concentrate financial power?
Tech tycoons have got the economics of AI wrong
Following DeepSeek’s breakthrough, the Jevons paradox provides less comfort than they imagine
Donald Trump’s economic warfare has a new front
The president has threatened to blow up the global tax system. Will allies be able to stop him?
Don’t let Donald Trump see our Big Mac index
America’s tariff-loving president could learn the wrong lessons from international burger prices